In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Shionogi has some big questions to answer if they plan to win an FDA panel’s backing for their new antibiotic.
While investigators have provided …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
